| Literature DB >> 24400161 |
Shalabh Srivastava1, Dimin Li2, Noel Edwards3, Ann-M Hynes3, Katrina Wood4, Mohamed Al-Hamed5, Anna C Wroe6, David Reaich6, Shabbir H Moochhala7, Paul A Welling2, John A Sayer1.
Abstract
A multiplex family was identified with biochemical and clinical features suggestive of Bartter's syndrome (BS). The eldest sibling presented with developmental delay and rickets at 4 years of age with evidence of hypercalciuria and hypokalemia. The second sibling presented at 1 year of age with urinary tract infections, polyuria, and polydipsia. The third child was born after a premature delivery with a history of polyhydramnios and neonatal hypocalcemia. Following corrective treatment she also developed hypercalciuria and a hypokalemic metabolic alkalosis. There was evidence of secondary hyperreninemia and hyperaldosteronism in all three siblings consistent with BS. Known BS genes were screened and functional assays of ROMK (alias KCNJ1, Kir1.1) were carried out in Xenopus oocytes. We detected compound heterozygous missense changes in KCNJ1, encoding the potassium channel ROMK. The S219R/L220F mutation was segregated from father and mother, respectively. In silico modeling of the missense mutations suggested deleterious changes. Studies in Xenopus oocytes revealed that both S219R and L220F had a deleterious effect on ROMK-mediated potassium currents. Coinjection to mimic the compound heterozygosity produced a synergistic decrease in channel function and revealed a loss of PKA-dependent stabilization of PIP2 binding. In conclusion, in a multiplex family with BS, we identified compound heterozygous mutations in KCNJ1. Functional studies of ROMK confirmed the pathogenicity of these mutations and defined the mechanism of channel dysfunction.Entities:
Keywords: Hypercalciuria; KCNJ1; Kir1.1; ROMK; hypokalemia; missense mutation; potassium; salt wasting
Year: 2013 PMID: 24400161 PMCID: PMC3871474 DOI: 10.1002/phy2.160
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Clinical features of affected individuals and their parents
| Sibling 1 | Sibling 2 | Sibling 3 | Father | Mother | |
|---|---|---|---|---|---|
| Age at presentation | 4 years | 1 year | 1 year | N/A | N/A |
| Polyhydramnios | Unknown | Y | Y | N | N |
| Polydipsia | Y | Y | Y | N | N |
| Sensorineural deafness | N | N | N | N | N |
| Learning difficulties | Y | Y | Y | N | N |
| Serum potassium (μmol/L) (NR 3.5–5.3) | 2.5–3 | 3.9 | 2.5–3 | 4.4 | 3.8 |
| Serum bicarbonate (μmol/L) (NR 22–29) | 30 | 25 | 23 | 22 | 23 |
| Serum calcium (μmol/L) (NR 2.12–2.6) | 2.05 | 1.89 | 1.85 | 2.4 | 2.35 |
| Serum magnesium (mmol/L) (NR 0.7–1.0) | 0.68 | 0.54 | 0.64 | N/A | N/A |
| Serum creatinine (μmol/L) (NR 55–95) | 65 | 117 | 54 | 42 | 78 |
| Renin (nmol/L h−1) (NR 2.8–4.5) | >50 | 3.6 | N/A | N/A | N/A |
| Aldosterone (pmol/L) (NR 100–450) | 345 | 5665 | N/A | N/A | N/A |
| Urine calcium:creatinine ratio (mmol/mmol creatinine) (NR 0–0.7) | 1.25 | 1.41 | 3.2 | Not done | Not done |
| Renal biopsy | Occasional foci of calcification around tubules JGA hyperplasia | Occasional foci of calcification around tubules JGA hyperplasia | Not biopsied | Not biopsied | Not biopsied |
| Renal ultrasound scan | Nephrocalcinosis | Nephrocalcinosis | Nephrocalcinosis | Not performed | No nephrocalcinosis |
| Systolic blood pressure (mmHg) | Normotensive 80–100 | Normotensive 70–80 | Normotensive 70–80 | Normotensive 130 | Normotensive 120 |
NR, normal range; N/A, not available.
Figure 1Clinical and molecular genetic analysis of Bartter's syndrome patients. Hyperplasia of juxtaglomerular apparatus is demonstrated on renal histology in (A) sibling 1 and (B) sibling 2. (C) Renal USS demonstrates nephrocalcinosis in sibling 3. (D) KNCJ1 sequencing identifies compound heterozygous mutations in all three affected p.S219R/p.L220F segregating from each parent.
Figure 2Homology modeling of ROMK. (A) Crystal structure of chicken Kcnj12/Kir2.2 (Hansen et al. 2011). One of the four Kcnj12 monomers forming the potassium channel is highlighted in orange. (B) Putative structure of the ROMK monomer (green) compared with chicken Kcnj12 (orange). The black box denotes the position of S219 and L220 in ROMK. (C) Partial amino acid sequence alignment of the human KCNJ family. (D) Putative position of S219 and L220 in ROMK and the homologous residues in chicken Kcnj12 (S221 and H222, respectively).
Figure 3Comparison of the properties of wild-type (WT) and mutant ROMK channels in Xenopus oocytes. Shown are families of whole-cell currents in oocytes injected with ROMK cRNA-encoding WT, mutant cRNA (S219R and L220F), or combinations of both to mimic heterozygosity and compound heterozygosity. Oocytes were held at −60 mV and clamped in 20 mV increments from −120 mV to +60 mV in 20 mV steps (5 mmol/L potassium).
Figure 4Effect of S219R and L220F mutations on ROMK channel activity. Relative outward potassium currents recorded by two-electrode voltage -clamp in Xenopus oocytes expressing ROMK. Oocytes were injected with 250 pg cRNA-encoding wild type (WT), S219R, or L220F mutant channel subunits. To mimic the compound heterozygous state of the patients, oocytes were coinjected with mixtures (given in parentheses) of the different cRNAs (250 pg in total). Data are mean ± SEM (n = 18 oocytes/group, from three frogs). ***P < 0.001; **P < 0.01; ns, P > 0.05 versus WT potassium current. #P < 0.001 versus WT+S219R current.
Figure 5L220F affects phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent gating of ROMK. Whole-cell potassium currents recorded in Xenopus oocytes coexpressing the M1 receptor with ROMK channels comprising wild type (WT) and/or L220F mutant subunits. Relative doses are given in parentheses. Data are expressed as the percent inhibition of the potassium current induced by exposure (10 min) to carbachol (25 μmol/L) and are mean ± SEM (n = 12–15 oocytes/group, from three frogs). ***P < 0.001; ns, P > 0.05 versus inhibition of WT potassium current.